相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Dupilumab provides long-term efficacy for up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
A. Blauvelt et al.
Revue Francaise d Allergologie (2022)
Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin
Ana B. Pavel et al.
ALLERGY (2021)
Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis
Helen He et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
Atopic dermatitis displays stable and dynamic skin transcriptome signatures
Lena Mobus et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
New treatments in atopic dermatitis
Neha Puar et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)
Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial
J. I. Silverberg et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
A. Wollenberg et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis
Maria Helena Rohner et al.
ALLERGY (2021)
A basophil-neuronal axis promotes itch
Fang Wang et al.
CELL (2021)
Periostin, an Emerging Player in Itch Sensation
Takashi Hashimoto et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)
Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial
Elaine C. Siegfried et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
Michael E. Wechsler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
Brett King et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Thomas Bieber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
Andrew Menzies-Gow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Pruritus as a Distinctive Feature of Type 2 Inflammation
Simone Garcovich et al.
VACCINES (2021)
27424 Infections in adults with moderate-to-severe atopic dermatitis treated with dupilumab: long-term data from an open-label extension (OLE) study
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials
Emma Guttman-Yassky et al.
LANCET (2021)
Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial
Amy S. Paller et al.
PEDIATRIC DRUGS (2021)
OX40L-OX40 Signaling in Atopic Dermatitis
Masutaka Furue et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
Masayoshi Harigai et al.
MODERN RHEUMATOLOGY (2020)
Regulation of Immunity and allergy by helminth parasites
Rick M. Maizels
ALLERGY (2020)
Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis
Thomas Bieber
ALLERGY (2020)
Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis
Eunhye G. Kang et al.
ALLERGY (2020)
The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets
Julie K. Nguyen et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2020)
Treatment of atopic dermatitis with ruxolitinib cream (JAKI/JAK2 inhibitor) or triamcinolone cream
Brian S. Kim et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
Emma Guttman-Yassky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood
Tali Czarnowicki et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis A Phase 3 Randomized Clinical Trial
Eric L. Simpson et al.
JAMA DERMATOLOGY (2020)
Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial
Susan Chan et al.
JAMA PEDIATRICS (2020)
Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation
Audrey Le Floc'h et al.
ALLERGY (2020)
Phenotypes and endotypes in eosinophilic esophagitis
Melanie A. Ruffner et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2020)
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials
E. L. Simpson et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis
Giulia Gasparini et al.
CYTOKINE (2020)
The Role of Th17-Related Cytokines in Atopic Dermatitis
Makoto Sugaya
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Reconciling innate and acquired immunity in atopic dermatitis
Tetsuya Honda et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
Hidemi Nakagawa et al.
JOURNAL OF DERMATOLOGY (2020)
Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study
Hidemi Nakagawa et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Skin-infiltrating basophils promote atopic dermatitis-like inflammation via IL-4 production in mice
Yoshinori Yamanishi et al.
ALLERGY (2020)
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis A Randomized Clinical Trial
Margitta Worm et al.
JAMA DERMATOLOGY (2020)
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis A Phase 2b Randomized Clinical Trial
Emma Guttman-Yassky et al.
JAMA DERMATOLOGY (2020)
Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study
Hideto Kameda et al.
RHEUMATOLOGY (2020)
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis
Kevin L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
Jonathan Silverberg et al.
JAMA DERMATOLOGY (2020)
Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis
Masutaka Furue
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
Philippe Gevaert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Eric L Simpson et al.
LANCET (2020)
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Kenji Kabashima et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Adult chronic rhinosinusitis
Claus Bachert et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
JAK inhibitors and infections risk: focus on herpes zoster
Flavia Sunzini et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2020)
The OX40 Axis is Associated with Both Systemic and Local Involvement in Atopic Dermatitis
Julie Sophie Hohwu Elsner et al.
ACTA DERMATO-VENEREOLOGICA (2020)
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
Emma Guttman-Yassky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab
Patrick M. Brunner et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
Anniina T. Virtanen et al.
BIODRUGS (2019)
Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches
Matthew Moyle et al.
EXPERIMENTAL DERMATOLOGY (2019)
Janus kinases to jakinibs: from basic insights to clinical practice
Massimo Gadina et al.
RHEUMATOLOGY (2019)
Impact of Omalizumab on Food Allergy in Patients Treated for Asthma: A Real-Life Study
Alessandro Fiocchi et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
Role of innate lymphoid cells in allergic diseases
M. Asghar Pasha et al.
ALLERGY AND ASTHMA PROCEEDINGS (2019)
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
Lawrence F. Eichenfield et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
An Update on Interleukin-9: From Its Cellular Source and Signal Transduction to Its Role in Immunopathogenesis
Sushmita Chakraborty et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Group 2 Innate Lymphoid Cells (ILC2): Type 2 Immunity and Helminth Immunity
De'Broski R. Herbert et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
IL-33-Induced Atopic Dermatitis-Like Inflammation in Mice Is Mediated by Group 2 Innate Lymphoid Cells in Concert with Basophils
Yasutomo Imai et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents
Josef Brandstrom et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2019)
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
Silvio Danese et al.
GUT (2019)
Omalizumab for atopic dermatitis: evidence for and against its use
Jesper G. Holm et al.
GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA (2019)
IL-4 Augments IL-31/IL-31 Receptor Alpha Interaction Leading to Enhanced Ccl 17 and Ccl 22 Production in Dendritic Cells: Implications for Atopic Dermatitis
Sho Miake et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Claus Bachert et al.
LANCET (2019)
Interleukin-4 and interleukin-13 evoke scratching behaviour in mice
Michelle Campion et al.
EXPERIMENTAL DERMATOLOGY (2019)
IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases
Giuseppe Murdaca et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Dupilumab for treatment of food allergy
Manuel Jorge Rial et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
Ligelizumab for Chronic Spontaneous Urticaria
Marcus Maurer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis A Phase 2 Randomized Clinical Trial
Melinda J. Gooderham et al.
JAMA DERMATOLOGY (2019)
Use of Tape Strips to Detect Immune and Barrier Abnormalities in the Skin of Children With Early-Onset Atopic Dermatitis
Emma Guttman-Yassky et al.
JAMA DERMATOLOGY (2019)
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial
Eric L. Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Clinical significance of Janus Kinase inhibitor selectivity
Ernest H. Choy
RHEUMATOLOGY (2019)
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
William W. Busse et al.
LANCET RESPIRATORY MEDICINE (2019)
Pathophysiology of atopic dermatitis: Clinical implications
Jihyun Kim et al.
ALLERGY AND ASTHMA PROCEEDINGS (2019)
JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis
Laura Vian et al.
FRONTIERS IN IMMUNOLOGY (2019)
Functional interactions between innate lymphoid cells and adaptive immunity
Gregory E. Sonnenberg et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment
Emma Guttman-Yassky et al.
EXPERIMENTAL DERMATOLOGY (2018)
A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents
Atsuo Tanimoto et al.
EXPERIMENTAL DERMATOLOGY (2018)
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma
William W. Busse et al.
ADVANCES IN THERAPY (2018)
Epidemiology of atopic dermatitis in adults: Results from an international survey
S. Barbarot et al.
ALLERGY (2018)
The atopic march Critical evidence and clinical relevance
David A. Hill et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2018)
Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study
Elena Peeva et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE)
M. de Bruin-Weller et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-serve psoriasis: phase II, randomized, double-blind, placebo-controlled study
G. J. Schmieder et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Mast cell-neural interactions contribute to pain and itch
Kalpna Gupta et al.
IMMUNOLOGICAL REVIEWS (2018)
Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention
Jean-Frederic Colombel
INFLAMMATORY BOWEL DISEASES (2018)
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
Kevin L. Winthrop et al.
INFLAMMATORY BOWEL DISEASES (2018)
Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis
Zuzhen Ou et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
New mechanism underlying IL-31-induced atopic dermatitis
Jianghui Meng et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
IL-31: A new key player in dermatology and beyond
Isin Sinem Bagci et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Dupilumab: A New Paradigm for the Treatment of Allergic Diseases
J. Sastre et al.
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2018)
Identification of N-{cis-3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminolcyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
Michael L. Vazquez et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial
Emma Guttman-Yassky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
Eric L. Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Interleukin-33: Its Emerging Role in Allergic Diseases
Wen Ding et al.
MOLECULES (2018)
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Klaus F. Rabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The roles for innate lymphoid cells in the human immune system
L. Mazzurana et al.
SEMINARS IN IMMUNOPATHOLOGY (2018)
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
Reynold A. Panettieri et al.
LANCET RESPIRATORY MEDICINE (2018)
Tuning the Cytokine Responses: An Update on interleukin (IL)-4 and IL-13 Receptor Complexes
Ilkka S. Junttila
FRONTIERS IN IMMUNOLOGY (2018)
The molecular details of cytokine signaling via the JAK/STAT pathway
Rhiannon Morris et al.
PROTEIN SCIENCE (2018)
First Responders: Innate Immunity to Helminths
Juan M. Inclan-Rico et al.
TRENDS IN PARASITOLOGY (2018)
Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma
Florence Roufosse
FRONTIERS IN MEDICINE (2018)
Type 2 immunity: Expanding our view
Clare M. Lloyd et al.
SCIENCE IMMUNOLOGY (2018)
Ruxolitinib-associated infections: A systematic review and meta-analysis
Federico Lussana et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Type 2 immunity in tissue repair and fibrosis
Richard L. Gieseck et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis
M. Furue et al.
ALLERGY (2018)
Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies
Hendrik Schulze-Koops et al.
RHEUMATOLOGY (2017)
IL-33: biological properties, functions, and roles in airway disease
Li Yin Drake et al.
IMMUNOLOGICAL REVIEWS (2017)
A molecular mechanism for IL-4 suppression of loricrin transcription in epidermal keratinocytes: implication for atopic dermatitis pathogenesis
Lei Bao et al.
INNATE IMMUNITY (2017)
Regulation of TH17 Cells and Associated Cytokines in Wound Healing, Tissue Regeneration, and Carcinogenesis
Leonie Brockmann et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study
JianZhong Zhang et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis
Shunya Mashiko et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt et al.
LANCET (2017)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
Tezepelumab in Adults with Uncontrolled Asthma
Jonathan Corren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Necative Regulation of Type 2 immunity
Dimitri A. de Kouchkovsky et al.
TRENDS IN IMMUNOLOGY (2017)
Inflammatory responses and inflammation-associated diseases in organs
Linlin Chen et al.
Oncotarget (2017)
Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies
Masutaka Furue et al.
ALLERGOLOGY INTERNATIONAL (2017)
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Geoffrey L. Chupp et al.
LANCET RESPIRATORY MEDICINE (2017)
Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch
Landon K. Oetjen et al.
CELL (2017)
Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors
Katharina Welsch et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
Jeffrey R. Curtis et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?
Nicholas K. Mollanazar et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2016)
Targeting key proximal drivers of type 2 inflammation in disease
Namita A. Gandhi et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
IL-25 Receptor Expression on Airway Dendritic Cells after Allergen Challenge in Subjects with Asthma
Damian Tworek et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma Effects Across a Broad Range of Eosinophil Counts
Jonathan Corren et al.
CHEST (2016)
Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study
Njira Lugogo et al.
CLINICAL THERAPEUTICS (2016)
Unintended Immunological Consequences of Biologic Therapy
Sarah E. Henrickson et al.
CURRENT ALLERGY AND ASTHMA REPORTS (2016)
Innate lymphoid cell regulation of adaptive immunity
David R. Withers
IMMUNOLOGY (2016)
The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves
Micha Feld et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin
Hitokazu Esaki et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Interleukin-4 Downregulation of Involucrin Expression in Human Epidermal Keratinocytes Involves Stat6 Sequestration of the Coactivator CREB-Binding Protein
Lei Bao et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2016)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
E. L. Simpson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
Nicola A. Hanania et al.
LANCET RESPIRATORY MEDICINE (2016)
IL-25 and IL-33 induce Type 2 inflammation in basophils from subjects with allergic asthma
Brittany M. Salter et al.
RESPIRATORY RESEARCH (2016)
Past, present, and future for biologic intervention in atopic dermatitis
M. D. Howell et al.
ALLERGY (2015)
Atopic Dermatitis: Global Epidemiology and Risk Factors
Sophie Nutten
ANNALS OF NUTRITION AND METABOLISM (2015)
Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways
David A. Ewald et al.
BMC MEDICAL GENOMICS (2015)
Expression of Neuropeptides, Neurotrophins, and Neurotransmitters in the Skin of Patients with Atopic Dermatitis and Psoriasis
A. A. Kubanov et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2015)
A Brief Journey through the Immune System
Karim M. Yatim et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production
Jinfang Zhu
CYTOKINE (2015)
Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions
Dhavalkumar D. Patel et al.
IMMUNITY (2015)
Interleukin-4 Receptor α Signaling in Myeloid Cells Controls Collagen Fibril Assembly in Skin Repair
Johanna A. Knipper et al.
IMMUNITY (2015)
The Interleukin-33-p38 Kinase Axis Confers Memory T Helper 2 Cell Pathogenicity in the Airway
Yusuke Endo et al.
IMMUNITY (2015)
The translational revolution and use of biologics in patients with inflammatory skin diseases
Shinji Noda et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
The 3 major types of innate and adaptive cell-mediated effector immunity
Francesco Annunziato et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization
Shinji Noda et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
A Novel IL-25 Signaling Pathway through STAT5
Ling Wu et al.
JOURNAL OF IMMUNOLOGY (2015)
TSLP Directly Interacts with Skin-Homing Th2 Cells Highly Expressing its Receptor to Enhance IL-4 Production in Atopic Dermatitis
Kazuki Tatsuno et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2015)
Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo
Atsuo Tanimoto et al.
INFLAMMATION RESEARCH (2015)
Type 2 cytokines: mechanisms and therapeutic strategies
Thomas A. Wynn
NATURE REVIEWS IMMUNOLOGY (2015)
Interferon-Stimulated Genes: A Complex Web of Host Defenses
William M. Schneider et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
Basophils Promote Innate Lymphoid Cell Responses in Inflamed Skin
Brian S. Kim et al.
JOURNAL OF IMMUNOLOGY (2014)
TNF-α and Th2 Cytokines Induce Atopic Dermatitis-Like Features on Epidermal Differentiation Proteins and Stratum Corneum Lipids in Human Skin Equivalents
Mogbekeloluwa O. Danso et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Role of Histamine H1 and H4 Receptors in Atopic Dermatitis: From Basic Research to Clinical Study
Yusuke Ohsawa et al.
ALLERGOLOGY INTERNATIONAL (2014)
Periostin in Skin Tissue and Skin-Related Diseases
Yukie Yamaguchi
ALLERGOLOGY INTERNATIONAL (2014)
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
Kevin L. Winthrop et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Cytokine mediated tissue fibrosis
Lee A. Borthwick et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2013)
The Epithelial Cell-Derived Atopic Dermatitis Cytokine TSLP Activates Neurons to Induce Itch
Sarah R. Wilson et al.
CELL (2013)
Thymic stromal lymphopoietin expression is increased in the horny layer of patients with atopic dermatitis
Y. Sano et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Th9 Cells Drive Host Immunity against Gastrointestinal Worm Infection
Paula Licona-Limon et al.
IMMUNITY (2013)
TSLP Elicits IL-33-Independent Innate Lymphoid Cell Responses to Promote Skin Inflammation
Brian S. Kim et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Granulocytes in Helminth Infection - Who is Calling the Shots?
B. L. Makepeace et al.
CURRENT MEDICINAL CHEMISTRY (2012)
IL-31 regulates differentiation and filaggrin expression in human organotypic skin models
Christian Cornelissen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma
Aarti Shikotra et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Ian D. Pavord et al.
LANCET (2012)
Type II-Activated Murine Macrophages Produce IL-4
Anne Camille La Flamme et al.
PLOS ONE (2012)
The JAK/STAT Pathway
Douglas A. Harrison
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2012)
IgE, Mast Cells, and Eosinophils in Atopic Dermatitis
Fu-Tong Liu et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2011)
Contrasting pathogenesis of atopic dermatitis and psoriasis-Part II: Immune cell subsets and therapeutic concepts
Emma Guttman-Yassky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
MECHANISMS OF DISEASE Filaggrin Mutations Associated with Skin and Allergic Diseases
Alan D. Irvine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Interferon-stimulated genes and their antiviral effector functions
John W. Schoggins et al.
CURRENT OPINION IN VIROLOGY (2011)
IgE, mast cells, basophils, and eosinophils
Kelly D. Stone et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Overview of the immune response
David D. Chaplin
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
IL25 elicits a multipotent progenitor cell population that promotes TH2 cytokine responses
Steven A. Saenz et al.
NATURE (2010)
The histamine H4 receptor is functionally expressed on TH2 cells
Ralf Gutzmer et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6
Byung Eui Kim et al.
CLINICAL IMMUNOLOGY (2008)
Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Rα, IL-13Rα1, and γc regulates relative cytokine sensitivity
Ilkka S. Junttila et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells
Yui-Hsi Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Cytokine modulation of atopic dermatitis filaggrin skin expression
Michael D. Howell et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2007)
TSLP: An epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation
Yong-Jun Liu et al.
ANNUAL REVIEW OF IMMUNOLOGY (2007)
Membrane-bound eotaxin-3 mediates eosinophil transepithelial migration in IL-4-stimulated epithelial cells
Qian Yuan et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
IL-4 induces expression of TARC/CCL17 uia two STAT6 binding sites
Gerald Wirnsberger et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus
MD Howell et al.
IMMUNITY (2006)
IL-31: A new link between T cells and pruritus in atopic skin inflammation
E Sonkoly et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)
TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand
T Ito et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis
JM Oldhoff et al.
ALLERGY (2005)
Fibrotic disease and the TH1/TH2 paradigm
TA Wynn
NATURE REVIEWS IMMUNOLOGY (2004)
The Janus kinases (Jaks)
K Yamaoka et al.
GENOME BIOLOGY (2004)
Regulation of JAK-STAT signalling in the immune system
K Shuai et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP
V Soumelis et al.
NATURE IMMUNOLOGY (2002)
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
W Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2001)
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
M Solèr et al.
EUROPEAN RESPIRATORY JOURNAL (2001)
Adhesion molecule profiles in atopic dermatitis vs. allergic contact dermatitis: pharmacological modulation by cetirizine
M Boone et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2000)